Summary of Absci's Conference Call Company Overview - **Company**: Absci - **Industry**: AI Drug Discovery - **Focus**: Clinical stage company leveraging AI for drug discovery, particularly in the field of regenerative medicine and hair regrowth. Key Points and Arguments AI Drug Discovery Platform - Absci is positioned as a clinical stage AI drug discovery company, emphasizing the importance of assets in the clinic and their readouts [4][10] - The company is excited about the integration of agentic AI into early-stage workflows, which allows for rapid identification of novel drug targets and validation of mechanisms [5][6][7] Long-term Value Creation Strategy - The primary focus for long-term value creation is on the assets themselves, with the platform serving as a critical enabler [10] - Absci aims to balance internal drug development with external partnerships to maximize value [8][10] ABS-201: Prolactin Receptor Antibody - ABS-201 targets androgenic alopecia and is seen as a potential game changer in hair regrowth therapies [13][14] - The total addressable market (TAM) in the U.S. for this indication is estimated to exceed $25 billion, with a development cost projected to be under $100 million [18][19] - The company anticipates rapid trial recruitment and aims for approval around 2030 [20][38] Market Demand and Patient Insights - There is a significant demand for hair regrowth solutions, with many patients dissatisfied with current treatments like minoxidil [14][22] - ABS-201 is expected to attract both existing patients and those who have previously avoided standard treatments [22][23] Efficacy and Safety Data - Preclinical studies in stump-tailed macaques showed promising results, including full hair regrowth and durability for over four years post-treatment [25][26] - The company is confident in achieving comparable or superior efficacy to existing treatments based on receptor occupancy data [27] Clinical Development Timeline - The ongoing studies include a single ascending dose (SAD) and a multiple ascending dose (MAD) study, with interim readouts expected in the second half of the year [28][29] - Plans to initiate a Phase 2 study for endometriosis are set for Q4 of this year, leveraging the same prolactin receptor mechanism [44] Commercial Strategy - Absci plans to initially launch ABS-201 through dermatologists, with a long-term vision for direct-to-consumer (DTC) marketing [47][48] - The company aims to build a strong brand reputation similar to successful consumer-facing products in the market [48] Pipeline and Future Developments - Absci is actively engaged in discussions for potential partnerships for other pipeline assets, particularly those that require significant capital for development [51][56] - The focus remains on leveraging the platform to create new assets while considering out-licensing opportunities for earlier-stage programs [55][56] Market Perception and Analyst Insights - There is a disconnect between the perceived value of the ABS-201 program and its current stock price, with analysts struggling to incorporate its potential into their models [62] - The company believes that as data emerges, this gap will close, leading to a more favorable market perception [62] Additional Important Insights - The psychological impact of hair loss on patients is significant, indicating that treatments like ABS-201 could address both physical and emotional needs [49] - The evolving landscape of preventative care and consumerization in healthcare is shaping Absci's approach to market entry and patient engagement [45][48]

Core Insights - Lux Capital has closed a $1.5 billion ninth fund, marking the largest fund in the firm's history [1] - Despite a decline in new VC funds raised in the U.S. to a 10-year low in 2025, limited partners continue to invest in Lux Capital [1] Investment Focus - The firm has a history of investing in defense technologies, which have become highly sought after due to recent geopolitical shifts [2] - Lux was an early investor in Anduril, valued at $30.5 billion, and Applied Intuition, valued at $15 billion, both of which have secured significant contracts with the Pentagon [2] AI Investments - Lux has made early investments in AI startups prior to the industry's rapid growth following the launch of ChatGPT [3] - Notable early-stage AI investments include Hugging Face, Runway AI, and MosaicML, the latter of which was acquired by Databricks for $1.3 billion in 2023 [3] Exits and Performance - The firm has achieved significant exits from investments, including Recursion Pharmaceuticals, which went public in 2021, and Auris Health, sold to Johnson & Johnson for up to $6 billion in 2019 [4] - The latest fundraising effort has increased Lux's total assets under management to $7 billion [4]

Recursion Pharmaceuticals Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS: RXRX) - **Event**: Jefferies London Healthcare Conference - **Date**: November 18, 2025 Key Points Leadership Transition - Najat Khan has taken over as CEO, with Chris Gibson remaining as Chair of the Board, indicating a smooth leadership transition and continuity in strategic direction [5][8] Strategic Focus Areas 1. **AI-Driven Therapeutics**: The company aims to leverage its integrated AI technology stack to develop differentiated therapeutics, emphasizing the importance of proprietary data generation [6][12] 2. **Operational Discipline**: Recursion has reduced operating costs by 35% while maintaining external catalysts, showcasing a commitment to financial discipline [7] 3. **Talent Acquisition**: The company highlights the importance of having a bilingual team that understands both AI and biology to drive innovation [7][20] Unique Platform and Data Strategy - Recursion differentiates itself by building proprietary datasets, with 65 petabytes of data, 40 petabytes of which are proprietary, allowing for unique AI model development [14][12] - The company has generated over $500 million from partnerships, indicating strong revenue generation for a pre-commercial biotech firm [13] Regulatory Engagement - Recursion is actively engaged with regulatory bodies in the U.S. and EU, particularly in the rare disease and oncology spaces, to navigate evolving guidelines and frameworks [22][23] - The company is focusing on reducing reliance on animal testing through predictive models and organoid approaches [24] Pipeline Highlights 1. **Familial Adenomatous Polyposis (FAP)**: - The company is developing a treatment for FAP, a rare disease affecting approximately 50,000 patients in the U.S. and EU, with promising early data showing a 30-80% reduction in polyps [27][28] - The treatment aims to provide an alternative to colectomy, significantly impacting patient quality of life [27] - Upcoming data expected next month will provide further insights into efficacy and safety [30] 2. **CDK7 and RBM39 Programs**: - The CDK7 program is in monotherapy dose escalation, with early activity observed and a focus on combination therapies in ovarian cancer [41][43] - The RBM39 program is a first-in-class degrader targeting DDR modulation, with early safety and pharmacokinetic data expected in the first half of next year [46] Market Considerations - The company is aware of safety signals related to LVEF depression and rash, common with MEK1/2 inhibitors, and is managing these through established protocols [34] - The potential pivotal program for FAP will likely involve composite endpoints, including polyp burden reduction and progression to surgery [38] Future Outlook - Recursion anticipates a busy 2026 with multiple catalysts and milestones across its pipeline and partnerships, indicating a strong growth trajectory [50] Additional Insights - The company emphasizes the importance of data provenance and model interpretability in regulatory discussions, which is critical for building trust with regulators [20][24] - Recursion's commitment to innovative approaches in drug discovery and development positions it well within the rapidly evolving biotech landscape [19][12]

Core Viewpoint - The biotech sector presents high-risk, high-reward investment opportunities, particularly for companies like Absci, which has a market cap of $600 million [1] Company Overview - Absci operates at the intersection of AI and biotechnology, leveraging machine learning and automation for drug discovery and development [2] - The company is positioned to lead a new generation of therapeutics, but its early-stage status and execution risks must be considered [2] Drug Discovery and Pipeline - Absci utilizes generative AI to model and design new therapeutics, potentially shortening R&D timelines [3] - The company has multiple drug candidates in clinical trials, including ABS-101 for IBD and ABS-201 for androgenic alopecia, with ABS-101 having launched a Phase 1 trial [3] Partnerships and Collaborations - Absci has established partnerships with major players in the biotech and pharma sectors, including a multi-year partnership with Merck valued at up to $610 million [4] - Other collaborations include partnerships with medical dermatology company Almirall and various firms [4] Market Potential - The AI drug discovery market is projected to grow at a CAGR of nearly 30% from 2024 to 2030, reaching over $20 billion [5] - Absci's addressable market includes biologics, monoclonal antibodies, and therapeutic proteins, indicating significant growth potential [5] Financial Position - Absci raised approximately $64 million in July 2025, increasing its cash reserves to over $117 million, providing a financial runway into 2028 [6] - The company is well-positioned to attract strategic investments as demand in the AI biotech space grows [6] Risks and Challenges - Absci faces execution and clinical risks, with no commercialized therapies currently available [7] - The company relies on research collaborations for revenue generation, which may concern investors [7] - The competitive landscape includes numerous rivals and legacy pharma players expanding their AI capabilities, adding uncertainty to Absci's growth [8] Analyst Sentiment - Analysts are generally optimistic about Absci, with six out of seven assigning a Buy rating and forecasting an upside potential of over 110% [9]

Core Viewpoint - NYB has entered into a business combination agreement with RF Acquisition Corp II, aiming to become a publicly listed company on Nasdaq under the ticker symbol "NYB" [1][9]. Company Overview - NYB is an AI-driven drug discovery and biotechnology company, recognized for its Vecura™ AI platform powered by the proprietary Drug-Target Interaction Graph Neural Network (DTIGN) [3][13]. - The company is developing one of the world's largest AI-curated natural compound libraries in collaboration with global technology leaders such as NVIDIA, HP, and Equinix [3][14]. Business Combination Details - The Proposed Transaction values NYB at approximately $1.5 billion in pre-transaction equity value, with existing shareholders retaining a majority of the Combined Company's outstanding shares [9][10]. - NYB will designate a majority of the board of directors for the Combined Company [2][9]. Pipeline and Innovations - NYB's drug discovery efforts have led to the identification of multiple nature-inspired small molecules targeting oncology, cardiovascular health, and mental health, with candidates like NB-A002 targeting the ILF2 protein [4][5]. - The global DNA Damage Response (DDR) therapy market is currently valued at $8.3 billion and is expected to reach $19.5 billion by the mid-2030s, indicating significant market potential for NYB's lead candidate [6]. Strategic Collaborations - NYB has established a joint laboratory with Nanyang Technological University (NTU), focusing on advancing AI-driven drug discovery and harnessing the therapeutic potential of natural compounds [7][14]. - The collaboration aims to develop next-generation AI engines to support drug discovery across various therapeutic areas [7]. Management Commentary - Management expresses confidence in NYB's unique position to transform medicine by addressing high unmet medical needs through its innovative AI-powered drug discovery platform [8].